TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06990867: Optimizing Reperfusion to Improve Outcomes and Neurologic Function

Sponsor: Corxel Pharmaceuticals · Phase: PHASE2/PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 740 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,644,872

Rescue Site Savings

+$2,414,136

Unlock Full NCT06990867 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06990867 Rescue Dossier →